CORE--SCIENTIFIC

核心--科学

基本信息

  • 批准号:
    6098274
  • 负责人:
  • 金额:
    $ 24.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1999
  • 资助国家:
    美国
  • 起止时间:
    1999-07-01 至 2000-06-30
  • 项目状态:
    已结题

项目摘要

The metabolic fate of the amyloid precursor protein (APP) is regulated by protein phosphorylation. Activation of protein kinase C (PKC), or inhibition of protein phosphatase-1 (PP-1) stimulates processing of APP through the non-amyloidogenic, alpha-secretase pathway. A greater understanding of the signal transduction pathways that control the intracellular trafficking and processing of APP, and govern the production and secretion of the A-beta amyloid protein (A/beta), may lead to novel therapeutic targets for the treatment of Alzheimer's disease. A multi-disciplinary approach is proposed in this Program Project to define the cellular role of APP and the molecular basis of the phosphorylation-dependent regulation of APP metabolism. Studies will be performed at several levels of organizational complexity, encompassing in vitro biochemical studies with purified molecules, cell biological systems to explore intracellular trafficking events, and studies in intact animals analyzing changes in APP metabolism resulting from targeted deletion of specific PP-1 isoforms and two endogenous inhibitors of PP-1 Core B is designed to provide a range of technical support services to the other members of the Program Project. The centralized organization of support functions will facilitate a reliable, efficient, and cost- effective means to ensure an adequate supply of materials. The Core will be responsible for the preparation and maintenance of adequate supplies of key reagents (Specific Aim 1), including purified protein kinases, protein phosphatases and protein and peptide inhibitors of these enzymes. The Core will provide advice and coordinate the utilization of other protein chemical support functions, such as peptide synthesis, protein sequencing, and mass spectroscopy. Domain-specific antibodies for APP and its metabolites have been essential tools for the study of APP processing. The Core will maintain stocks of antibodies in current use, and will produce additional polyclonal and phosphorylation state-specific antibodies and assist in the development of assays for their use (Specific Aim 2). The Core will maintain the colonies of knock-out mice and provide the required number of animals that are proposed for study in Project 3 (Specific Aim 3). These will include the knock-out mice for phosphatase inhibitor-1 (already created), inhibitor-2 (to be produced in project 3), PP-1alpha, and PP-1gamma (to be provided by other collaborators). "Double" knock-outs of l-1/l-2 and PP-1alpha/gamma will be produced by cross-breeding.
淀粉样蛋白前体蛋白(APP)的代谢命运受到调节

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW J CZERNIK其他文献

ANDREW J CZERNIK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW J CZERNIK', 18)}}的其他基金

SYNAPSINS--POTENTIAL MEDIATORS OF NEUROTROPHIN ACTION
突触蛋白——神经营养因子作用的潜在介质
  • 批准号:
    6563315
  • 财政年份:
    2002
  • 资助金额:
    $ 24.16万
  • 项目类别:
Phosphoantibodies as Research Tools to Study the NMDAR
磷酸化抗体作为 NMDAR 研究工具
  • 批准号:
    6484433
  • 财政年份:
    2002
  • 资助金额:
    $ 24.16万
  • 项目类别:
CORE--SCIENTIFIC CORE
核心--科学核心
  • 批准号:
    6563317
  • 财政年份:
    2002
  • 资助金额:
    $ 24.16万
  • 项目类别:
CORE--SCIENTIFIC CORE
核心--科学核心
  • 批准号:
    6413585
  • 财政年份:
    2001
  • 资助金额:
    $ 24.16万
  • 项目类别:
SYNAPSINS--POTENTIAL MEDIATORS OF NEUROTROPHIN ACTION
突触蛋白——神经营养因子作用的潜在介质
  • 批准号:
    6413583
  • 财政年份:
    2001
  • 资助金额:
    $ 24.16万
  • 项目类别:
CORE--SCIENTIFIC CORE
核心--科学核心
  • 批准号:
    6299405
  • 财政年份:
    2000
  • 资助金额:
    $ 24.16万
  • 项目类别:
CORE--SCIENTIFIC
核心--科学
  • 批准号:
    6325701
  • 财政年份:
    2000
  • 资助金额:
    $ 24.16万
  • 项目类别:
SYNAPSINS--POTENTIAL MEDIATORS OF NEUROTROPHIN ACTION
突触蛋白——神经营养因子作用的潜在介质
  • 批准号:
    6299403
  • 财政年份:
    2000
  • 资助金额:
    $ 24.16万
  • 项目类别:
CORE--SCIENTIFIC CORE
核心--科学核心
  • 批准号:
    6300746
  • 财政年份:
    2000
  • 资助金额:
    $ 24.16万
  • 项目类别:
CORE--SCIENTIFIC FACILITIES
核心——科学设施
  • 批准号:
    6111336
  • 财政年份:
    1999
  • 资助金额:
    $ 24.16万
  • 项目类别:

相似海外基金

Development of B cell functional studies on primary antibody deficiencies
一抗缺陷 B 细胞功能研究的进展
  • 批准号:
    502607
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
Thymus antibody-secreting cells: major players in autoimmunity.
胸腺抗体分泌细胞:自身免疫的主要参与者。
  • 批准号:
    502578
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
ICF: AbVax Combination vaccination and broadly neutralising antibody therapy in HIV to induce a protective Tcell vaccinal effect, a mechanistic study
ICF:AbVax 联合疫苗接种和广泛中和 HIV 抗体疗法诱导保护性 T 细胞疫苗效应,一项机制研究
  • 批准号:
    MR/Y008847/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Research Grant
Enabling The Targeted Delivery Of DNA G-quadruplex Ligands using a Novel Antibody DAR-1 Platform
使用新型抗体 DAR-1 平台实现 DNA G 四链体配体的靶向递送
  • 批准号:
    BB/Y002180/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Research Grant
Antibody-Palladium Conjugates for Bioorthogonal Anti-Cancer Prodrug Activation
用于生物正交抗癌前药激活的抗体-钯缀合物
  • 批准号:
    EP/Y024540/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Fellowship
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
  • 批准号:
    24K19237
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A Semi-Automated Antibody-Discovery Platform to Target Challenging Biomolecules
针对具有挑战性的生物分子的半自动化抗体发现平台
  • 批准号:
    MR/Y003616/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Fellowship
Monitoring antibody protection against SARS-CoV-2 variants
监测抗体对 SARS-CoV-2 变体的保护作用
  • 批准号:
    MR/Y033698/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
  • 批准号:
    479128
  • 财政年份:
    2023
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Operating Grants
Pharmacokinetic analysis of antibody drug conjugate in tumor cells utilizing synchrotron soft X-ray imaging
利用同步加速器软 X 射线成像对肿瘤细胞中抗体药物偶联物进行药代动力学分析
  • 批准号:
    23H03716
  • 财政年份:
    2023
  • 资助金额:
    $ 24.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了